the study for GVHD for CYP had 15 people as opposed to MSB 309 (paediatric)
not nearly enough data to accurately compare products but definitely interesting, worth keeping an eye out.
also, MSB was 1 - 2 infusions not 8-12....
i cant really find much documented studies for CYP, only one study is listed on their site which is what is referenced in the OP.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |